Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Is there a biomarker for which patients benefit from tarlatamab?
Related Questions
What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?
How do you determine your next line of therapy In ALK+ metastatic NSCLC patients who have widespread progression on first-line lorlatinib?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
What is your preferred treatment option after tarlatamab for patients with ES-SCLC?
How would you approach post-chemoradiation consolidation in a patient with stage III lung adenocarcinoma with an EGFR exon 18 G719A mutation and highly positive PD-L1 level?
Would you consider bevacizumab for a patient with SCLC who has asymptomatic brain metastasis progression after CNS radiation and while on maintenance immunotherapy?
How do you approach stage IIa squamous cell carcinoma of the lung with a PD-L1 level of 1-49% and no targetable mutations?
Would you continue tarlatamab in CNS-only progression of small cell cancer if there is no systemic disease?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?
